Sumary of Safety tops concerns in drive to develop, distribute COVID-19 vaccines:
- While experts are optimistic that multiple COVID-19 vaccine products will be available in late 2020 or early 2021, ongoing questions remain surrounding safety, ethics and distribution, according to panelists at ACR Convergence 2020..
- The first question posed to panelist Grace Lee, MD, of Stanford University, dealt with ensuring the safety of a vaccine in an accelerated development environment..
- of safety protocols in place for the COVID-19 vaccine development process, she commented on the hard reality of the situation..
- “We will have more safety data prior to approval than we do for many other vaccines going to the FDA for approval,”.
- The Vaccine Adverse Event Reporting System (VAERS) gathers relevant data, as does the National Healthcare Safety Network (NHSN), while the CDC vaccine safety program (V-SAFE) and even the department of defense (DOD) may be involved..
- Promising candidates, big numbers Speaking of huge numbers, Dan Barouch, MD, PhD, of Beth Israel Deaconess Medical Center and Harvard Medical School, said that there are “over 200”.
- has created a hierarchy of need — health care workers, front line workers, the elderly, those with comorbid conditions and then on to the general population — whether that will come to pass, or whether such a pattern will be followed on a worldwide scale remains to be seen..
- While Kolker acknowledged the safety measures taken in the development process outlined by Lee, he raised the question of whether a faster timeline would allow for all people of all races and ethnicities, or elderly or other high-risk populations, to be “adequately represented”…